Raymond F Suckow
Overview
Explore the profile of Raymond F Suckow including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sheline Y, Snider B, Beer J, Seok D, Fagan A, Suckow R, et al.
Neurology
. 2020 Sep;
95(19):e2658-e2665.
PMID: 32913021
Objective: To determine whether treatment with escitalopram compared with placebo would lower CSF β-amyloid 42 (Aβ) levels. Rationale: Serotonin signaling suppresses Aβ in animal models of Alzheimer disease (AD) and...
2.
Milak M, Rashid R, Dong Z, Kegeles L, Grunebaum M, Ogden R, et al.
JAMA Netw Open
. 2020 Aug;
3(8):e2013211.
PMID: 32785636
Importance: A single subanesthetic dose of ketamine produces an antidepressant response in patients with major depressive disorder (MDD) within hours, but the mechanism of antidepressant effect is uncertain. Objective: To...
3.
Chen B, Luna V, LaGamma C, Xu X, Deng S, Suckow R, et al.
Neuropsychopharmacology
. 2020 May;
45(9):1545-1556.
PMID: 32417852
Enhancing stress resilience in at-risk populations could significantly reduce the incidence of stress-related psychiatric disorders. We have previously reported that the administration of (R,S)-ketamine prevents stress-induced depressive-like behavior in male...
4.
Slifstein M, Abi-Dargham A, Girgis R, Suckow R, Cooper T, Divgi C, et al.
Psychopharmacology (Berl)
. 2019 Nov;
237(2):519-527.
PMID: 31773210
Rationale: F17464, a dopamine D3 receptor antagonist with relatively high D3 selectivity (70 fold vs D2 in vitro), exhibits an antipsychotic profile in preclinical studies, and therapeutic efficacy was demonstrated...
5.
Dong B, Shilpa B, Shah R, Goyal A, Xie S, Bakalian M, et al.
J Psychiatr Res
. 2019 Oct;
120:103-112.
PMID: 31654971
Major depressive disorder (MDD) is common, often under-treated and a leading cause of disability and mortality worldwide. The causes of MDD remain unclear, including the role of the endocannabinoid system....
6.
Grunebaum M, Galfalvy H, Choo T, Parris M, Burke A, Suckow R, et al.
J Psychiatr Res
. 2019 Sep;
119:32.
PMID: 31550622
No abstract available.
7.
Grunebaum M, Galfalvy H, Choo T, Parris M, Burke A, Suckow R, et al.
J Psychiatr Res
. 2019 Aug;
117:129-134.
PMID: 31415914
Ketamine shows promise as a rapidly-acting treatment for depression and suicidal ideation, but side effects and abuse potential limit its use. Understanding its mechanism of action could help develop analogous...
8.
Bodkin J, Coleman M, Godfrey L, Carvalho C, Morgan C, Suckow R, et al.
Biol Psychiatry
. 2019 Jul;
86(7):523-535.
PMID: 31279534
Background: The increased mutational burden for rare structural genomic variants in schizophrenia and other neurodevelopmental disorders has so far not yielded therapies targeting the biological effects of specific mutations. We...
9.
Balla A, Dong B, Shilpa B, Vemuri K, Makriyannis A, Pandey S, et al.
Neuropharmacology
. 2017 Nov;
131:200-208.
PMID: 29109060
Binge alcohol (ethanol) drinking is associated with profound adverse effects on our health and society. Rimonabant (SR141716A), a CB1 receptor inverse agonist, was previously shown to be effective for nicotine...
10.
Benham R, Hewage N, Suckow R, Engin E, Rudolph U
Behav Brain Res
. 2017 Oct;
338:186-189.
PMID: 29070432
No abstract available.